Comparison of clinical efficacy of serotonin receptor antagonists in highly emetogenic chemotherapy
Referencias
Additional references
Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark‐Snow R, Koeller JM, et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology 2006;24(18):2932‐47.
American Society of Health‐System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. American Journal of Health‐System Pharmacy 1999;56:729‐64.
Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997;54(2):273‐98.
Blake JC, Palmer JL, Minton NA, Burroughs AK. The pharmacokinetics of intravenous Ondansetron in patients with hepatic impairment. British Journal of Clinical Pharmacology 1993;35:441‐3.
Bloomer JC, Baldwin SJ, Smith GJ, et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of Granisetron. British Journal of Clinical Pharmacology 1994;38:273‐98.
Blower PR. 5‐HT3‐receptor antagonists and the cytochrome p450 system: clinical implications. Cancer Journal 2002;8(5):405‐14.
Blower PR. Granisetron: relating pharmacology to clinical efficacy. Supportive Care in Cancer 2003;11(2):93‐100.
Borison HL, McCarthy LE. Neuropharmacology of chemotherapy induced emesis. Drugs 1983;25:8‐17.
Clarke, MJ, Oxman AD. Cochrane and National Library of Medicine randomized controlled trial and controlled clinical trial criteria. Cochrane Reviewers` Handbook 4.2.3 (updated November 2004); Appendix 5a. Chichester, UK: John Wiley & Sons, Ltd, 2006.
Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. The American Journal of the Medical Sciences 1987;293:34‐44.
Cubeddu LX, Hoffman IS, Fuenmajor NT, et al. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide‐containing chemotherapy regimens. Journal of Clinical Oncology 1990;8:1721‐7.
Cubeddu L. Efficacy of Ondansetron (GR 38032F) and the role of serotonin in cisplatin‐induced nausea and vomiting. New England Journal of Medicine 1990;322:810‐6.
Davis MP, Homsi J. The importance of cytochrome P450 monoxygenase CYP2D6 in palliative medicine. Supportive Care in Cancer 2001;9:442‐51.
Del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to Ondansetron for prophylaxis of chemotherapy‐induced nausea and vomiting. Cancer 2000;89:2301‐8.
Herrstedt J, Aapro MS, Roila F, Kataja VV, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy‐induced nausea and vomiting (NV). Annals of Oncology 2005;16 Supplement 1:i77‐9.
Ettinger DS. Preventing chemotherapy‐induced nausea and vomiting: an update and a review of emesis. Seminars in Oncology 1995;22 (Suppl 10):6‐18.
Figg WD, Dukes GE, Pritchard JF, et al. Pharmacokinetics of Ondansetron in patients with hepatic insufficiency. Journal of Clinical Pharmacology 1996;36:206‐15.
Fozard JR, Mobarok ATM. Blockade of neuronal tryptamine receptors by metoclopramide. European Journal of Pharmacology 1978;49:109‐12.
Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high‐dose metoclopramide: randomised trials with placebo and plochlorperazine in patients with chemotherapy‐induced nausea and vomiting. New England Journal of Medicine 1981;305:905‐9.
Gralla R, Navari RM, Hesketh PJ, et al. Single dose Granisetron has equivalent anti‐emetic efficacy to intravenous Ondansetron for highly emetogenic cisplatin‐based chemotherapy. Journal of Clinical Oncology 1998;16:1568‐73.
Grunberg SM, Hansen M, Deuson R, et al. Incidence and impact of nausea/vomiting with modern antiemetic: Perception vs reality. Proc American Society of Clinical Oncology. 2003; Vol. 21:250a (abstr 996).
Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. The Oncologist 1999;4:191‐6.
Hoechst Marion Russel Inc. Anzemet (dolasetron mesylate) tablets and injection. Prescribing information. Hoechst Marion Russel. Kansas City, 1999.
Kaiser R, Sezer O, Papies A, et al. Patient‐tailored anti‐emetic treatment with 5‐hydroxytryptamine type 3 receptor antagonists according to cytochrome P450 2D6 genotypes. Journal of Clinical Oncology 2002;20:2805‐11.
Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Supportive Care in Cancer 2002;10:519‐22.
Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Supportive Care in Cancer 1994;2:297‐300.
Mendarte L, Aguas Compaired M, Martinez Bernabe M, Odena E, Rodriguez PG. Meta‐analysis of granisetron against ondansetron: efficacy and security in the prevention of acute emesis induced by chemotherapy with high doses of cisplatino [Meta‐analisis de granisetron frente a ondansetron: efficacia y seguridad en la prevencion de la emesis aguda inducida por quimioterapia con dosis altas de cisplatino]. Medicina Clinica (Barcelona) 2000;115:456‐60.
Moertel CG, Reitemeier RJ, Gage R. A controlled clinical evaluation of antiemetic drugs. JAMA 1963;186:116‐8.
Palmer R. Efficacy and safety of Granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Seminars in Surgical Oncology 21 1994;[suppl 5]:22‐5.
Perez EA, Hesketh P, Sandbach J, et al. Comparison of single‐dose oral Granisetron versus intravenous Ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double‐blind, randomised parallel study. Journal of Clinical Oncology 1998;16:754‐60.
Rhoda CL, Plosker GL, McTavish D. Tropisetron A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an anti‐emetic. Drugs 1993;46:925‐43.
Robinson KA Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150‐3.
Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. European Journal of Pharmacology 1994;262:R1‐2.
Siegel LJ, Longo DL. The control of chemotherapy‐induced emesis. Annals of Internal Medicine 1981;95:352‐9.
Strum SB, Mc Dermed JE, Opfell RW, et al. Intravenous metoclopramide: an effective antiemetic in cancer chemotherapy. JAMA 1982;247:2683‐6.
Tack J. Receptors of the enteric nervous system: potential targets for drug therapy. Gut 2000;47(Supplement 4):iv 20‐2.
The Medical Letter. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy. The Medical Letter 2004;46(1179):27‐8.
